Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00605423 · ClinicalTrials.gov registry record · Phase 2
The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00605423: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT00605423 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00605423, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Treatment of exudative age-related macular degeneration has been significantly improved by the advent of Lucentis™( which provides improved vision rather than simply stabilization) is common; however, monthly injections may be required to maintain this effect. It is hypothesized that sustained release fluocinolone acetonide will allow maintenance of the improved vision with fewer Lucentis injections.
Interventions
- DRUG Fluocinolone Acetonide/Medidur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00605423
The ClinicalTrials.gov registry entry for NCT00605423 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fluocinolone Acetonide/Medidur is the first listed.
NCT00605423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00605423 about?
NCT00605423 is a clinical study titled "The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot". Treatment of exudative age-related macular degeneration has been significantly improved by the advent of Lucentis™( which provides improved vision rather than simply stabilization) is common; however, monthly injections may be required to maintain this effect. It is hypothesized that sustained relea...
What is the current status of trial NCT00605423?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2008-01. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00605423?
The interventions under investigation include: Fluocinolone Acetonide/Medidur (DRUG).
Who is sponsoring clinical trial NCT00605423?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.